Medtronic, Inc. (MDT)

Check out top investors' recommendation for MDT
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
93.09
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It provides products to diagnose, treat, and manage heart rhythm disorders and heart failure, including implantable cardiac pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy devices, arctic front cardiac cryoablation catheters, arctic front cardiac cryoablation catheters, and patient management tools. The company also offers cardio vascular products, such as percutaneous coronary intervention device that is used to treat patients with coronary artery disease; renal denervation for the treatment of chronic uncontrolled hypertension; endovascular stent grafts to treat abdomen and thoracic regions of the aorta; peripheral vascular intervention that encompasses various procedures to treat patients with peripheral vascular disease; surgical valve replacement and repair products for damaged or diseased heart valves; transcatheter heart valves; a line of blood-handling products used in arrested heart surgeries; positioning and stabilization technologies that assist physicians performing beating heart surgery; and surgical ablation system, which allows cardiac surgeons to create ablation lines during cardiac surgery. In addition, it provides medical devices and implants that are used in the treatment of the spine and musculoskeletal system comprising thoracolumbar, cervical, and biologics products; neurostimulators for chronic pain, implantable drug delivery systems, and deep brain stimulation systems, as well as urology, fecal, and gastroenterology devices; and integrated diabetes management solutions. Further, the company offers products and therapies to treat diseases and conditions of the ear, nose, and throat, as well as certain neurological disorders; and image-guided surgery and intra-operative imaging systems. It also has a research collaboration with GI Dynamics, Inc. The company was founded in 1949 and is headquartered in Minneapolis, Minnesota.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Michael Matson Mizuho Securities USA Buy   Oct 09, '17     94.00  Oct 09, '18  N/A 
Steven Lichtman Oppenheimer & Co. Buy   Oct 09, '17     92.00  Oct 09, '18  N/A 
Joanne Wuensch BMO Capital Markets Buy   Sep 29, '17     92.00  Sep 29, '18  N/A 
Josh Jennings Cowen And Company Buy   Sep 27, '17     95.00  Sep 27, '18  N/A 
Glenn Novarro RBC Capital Markets Buy   Sep 22, '17     90.00  Sep 22, '18  N/A 
Amit Hazan Suntrust Robinson Humphrey Buy   Sep 11, '17     97.00  Sep 11, '18  N/A 
Matthew Taylor National Bank Financial Buy   Aug 23, '17     92.00  Aug 23, '18  N/A 
Michael Matson Mizuho Securities USA Buy   Aug 23, '17     95.00  Aug 23, '18  N/A 
Joanne Wuensch BMO Capital Markets Buy   Aug 22, '17     92.00  Aug 22, '18  N/A 
Steven Lichtman Oppenheimer & Co. Buy   Aug 22, '17       Aug 22, '18  N/A 
Josh Jennings Cowen And Company Buy   Aug 22, '17     95.00  Aug 22, '18  N/A 
Glenn Novarro RBC Capital Markets Buy   Aug 20, '17     90.00  Aug 20, '18  N/A 
Michael Matson Mizuho Securities USA Buy   Jul 18, '17     95.00  Jul 18, '18  N/A 
Larry Biegelsen Wells Fargo Securities, Llc Buy   Jul 10, '17       Jul 10, '18  N/A 
Raj Denhoy Jefferies & Co. Buy   Jun 27, '17     97.00  Jun 27, '18  N/A 
Steven Lichtman Oppenheimer & Co. Buy   Jun 26, '17       Jun 26, '18  N/A 
Matthew Taylor National Bank Financial Buy   May 25, '17     94.00  May 25, '18  N/A 
Michael Matson Mizuho Securities USA Buy   May 25, '17     95.00  May 25, '18  N/A 
Steven Lichtman Oppenheimer & Co. Buy   May 25, '17       May 25, '18  N/A 
Joanne Wuensch BMO Capital Markets Buy   May 25, '17     87.00  May 25, '18  N/A 
< previous12345